Change the World
The Top Ten
The Vaccine Makers
Pharmaceuticals
In the ceaseless tide of worry over the pandemic, it’s easy to forget how far we’ve come. It is nothing short of remarkable how quickly the pharmaceutical industry developed not one but several COVID-19 vaccines. Not even a year after the first regulatory approvals, well over 30% of the global populace has been fully vaccinated—a historic and humbling achievement. Still, the vaccine rollout has been deeply uneven, with poorer countries left lagging far behind richer counterparts that bought up most of the supply. Scientists and ethicists agree that the disparity is bad for humanity. Not only do inadequately vaccinated populations suffer more harm, they also risk becoming breeding grounds for fast-moving variants of the virus that might evolve to be vaccine-resistant. The Delta variant—and the intense economic uncertainty surrounding it—has provided an unwelcome glimpse of that future. That’s the thinking behind our No. 1 entry for this year’s Change the World list. While last year’s list honored the pharma industry’s unprecedented collaboration on beating the virus, this year Fortune is highlighting companies that are racing to expand access to vaccines, especially in the Global South. For more, read "COVID-19 vaccine makers fight the pandemic fight, worldwide."
Envision Group
Energy
As China aims for net-zero emissions by 2060, Envision is playing a key role. It was the world’s fourth-largest supplier of wind turbines in 2020. It also provides energy management services to more than 360 customers, including tech giants Microsoft, Accenture, and Amazon Web Services. In December, Envision joined other energy producers in an R&D initiative to push the cost of producing “green” hydrogen—hydrogen fuel made using renewable energy—to below $2 per kilogram, the point at which the clean-burning fuel can become a viable fossil-fuel alternative. Envision estimates it can get there in three years.
Costco Wholesale
General Merchandisers
In the war for retail talent during the pandemic, Costco Wholesale put its money where its mouth is. Already a leader in incentives like paid sick days, Costco in February raised the internal minimum wage for its 200,000-plus–person workforce to $16, keeping the pressure on competitors to pay their own workers more. Not long afterward, Amazon and Walmart each gave raises to hundreds of thousands of their workers. Costco’s reward for its efforts: double-digit percentage increases in sales—long after pandemic panic-buying eased—and customers as loyal as ever.
Banco Santander
Commercial Banks
Santander Brasil, a company of Santander Group, is green energy’s financial engine in the world’s sixth-largest nation by population. It has been involved in about $11 billion worth of green-power deals since 2012, having financed or structured roughly a third of Brazil’s wind-power projects. Santander has also made its solar-panel lending more generous, with longer payment terms and up to 100% financing, to foster more users. Santander Group, led by Executive Chairman Ana Botin, is a world leader in renewable energy project finance. For more information, watch this Fortune video.
Viatris
Pharmaceuticals
Viatris, the global drug maker that resulted from the recent merger of Mylan and Pfizer’s Upjohn unit, has transformed the treatment of HIV around world in the past five years. Working through public-private partnerships with organizations like Unitaid, the WHO-affiliated global health agency, and the Bill and Melinda Gates Foundation, the company introduced the first low-cost antiretroviral with dolutegravir, the recommended first-line treatment for HIV, expanding that drug’s access to the 35 million people living with the virus in low- and middle-income countries. Priced at just $75 per year, the product was game-changing, says Unitaid’s Robert Matiru, who notes that the same is true of the version—strawberry-flavored tablets that dissolve in liquid—that Viatris recently launched for children (adult drugs are not formulated for young patients, and their bitter taste makes them hard for kids to take). The children’s version also lowers the cost of treatment by 75%, to $120 per year. Moreover, Matiru marvels at the “record-pace” speed and professionalism with which Viatris, now the world’s largest provider of antiretrovirals, has developed these low-cost, state-of-the-art medicines for populations who previously had no way to get them.